Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
J Hum Hypertens ; 30(5): 309-14, 2016 May.
Artigo em Inglês | MEDLINE | ID: mdl-26178590

RESUMO

South Asians (SA) suffer from a higher burden of heart disease and stroke compared with White Caucasians (CA). We hypothesized that increased arterial stiffness in older adults of SA origin would be associated with greater cerebrovascular pulsatile pressure and flow characteristics compared with CA older adults. Forty-four SA and CA older adults, free of known cardiovascular and cerebrovascular diseases, were assessed. Vascular ageing was characterized by brachial-ankle pulse wave velocity, carotid pulse pressure, compliance coefficient (CC) and intima-media thickness (IMT). Duplex ultrasonography of the internal carotid arteries estimated anterior cerebral blood flow (aCBF) and cerebrovascular resistance (aCVR), and transcranial Doppler ultrasound quantified middle cerebral artery blood flow velocity, resistive index (RI) and pulsatility index (PI). Fasting blood samples were collected to assess glycaemic status, lipid profile and C-reactive protein. SA had higher carotid pulse pressure and lower CC indicating stiffer arteries compared with CA. Multiple regression analyses revealed that ethnic differences in arterial stiffness were associated with glycated haemoglobin level in SA. Among SA, an inverse association was observed between carotid CC and aCVR. In turn, aCVR was associated with a steeper reduction in aCBF in SA than in CA. IMT was strongly associated with greater PI and RI (r>0.81, P<0.001) in SA, whereas a weaker relationship for PI (r=0.46, P=0.03) and no significant relationship for RI were found in CA. The study found stronger associations between pulsatile cerebrovascular haemodynamics and structural and functional alterations in central arteries in SA that may underlie the elevated risk for cerebrovascular disease.


Assuntos
Circulação Cerebrovascular , Fluxo Pulsátil , Rigidez Vascular , Idoso , Idoso de 80 Anos ou mais , Ásia Ocidental/etnologia , Povo Asiático , Estudos Transversais , Humanos , Masculino , Pessoa de Meia-Idade , População Branca
2.
HIV Med ; 6(2): 79-90, 2005 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-15807713

RESUMO

BACKGROUND: Metabolic abnormalities are common in HIV-infected individuals and, although multifactorial in origin, have been strongly associated with antiretroviral therapy. METHODS: Using automated claims and clinical databases, combined with medical record data, we evaluated the burden of dyslipidaemia (DYS) and associated metabolic abnormalities among a cohort of 900 HIV-infected patients aged 18 years and older who received their care from a large multispecialty medical group between 1 January 1996 and 30 June 2002. A Cox proportional hazards model for DYS was developed. Resource use was compiled and subsequently costed with stratification to account for variable length of follow-up. RESULTS: Mean follow-up time was 3.3 years. DYS was present in 54% of the cohort and 3.4% experienced a cardiovascular (CV) event. Both unadjusted and adjusted results found patients with dyslipidaemia and cardiovascular events significantly more likely to have received protease inhibitor (PI) treatment for longer periods of time. In the Cox proportional hazards model the following factors were significantly associated with an increased risk for DYS: older age, white race, PI use and male sex. Diagnoses of hypertension, hepatitis C virus infection, depression or opportunistic infections were all negatively associated with a DYS diagnosis. When controlled for length of follow up, patients with DYS (and no CV-related events) incurred greater median and mean total average costs than patients without DYS or CV-related events. For patients with more than 2 years of follow up, these total cost differences were statistically significant (P<0.05). CONCLUSIONS: These findings indicate that DYS is common among patients with HIV infection and is associated with increased use of medical resources.


Assuntos
Antivirais/uso terapêutico , Doenças Cardiovasculares/virologia , Infecções por HIV/complicações , Inibidores da Protease de HIV/uso terapêutico , Hiperlipidemias/etiologia , Hipolipemiantes/uso terapêutico , Adulto , Fatores Etários , Terapia Antirretroviral de Alta Atividade , Antivirais/economia , Doenças Cardiovasculares/economia , Bases de Dados Factuais , Custos de Medicamentos , Feminino , Seguimentos , Infecções por HIV/tratamento farmacológico , Infecções por HIV/economia , Inibidores da Protease de HIV/economia , Custos de Cuidados de Saúde , Humanos , Hiperlipidemias/economia , Hipolipemiantes/economia , Masculino , Modelos de Riscos Proporcionais , Estudos Retrospectivos , Fatores Sexuais , População Branca
3.
Clin Infect Dis ; 31(4): E20-2, 2000 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-11049808

RESUMO

Progressive multifocal leukoencephalopathy (PML) is a well recognized demyelinating neurological disorder caused by JC virus. Idiopathic CD4(+) lymphocytopenia (ICL) is a syndrome first described by the Centers for Disease Control and Prevention as a CD4(+) count <300 cells/mm(3) or a CD4(+) count that is <20% of the total T cell count on 2 occasions, with no evidence of human immunodeficiency virus (HIV) infection on testing, and absence of any defined immunodeficiency or therapy that depresses the levels of CD4(+) T cells. To the best of our knowledge, this is the third reported case of PML and ICL, and also the first reported case of the use of cidofovir to treat PML in a patient not infected with human immunodeficiency virus.


Assuntos
Leucoencefalopatia Multifocal Progressiva/complicações , Organofosfonatos , T-Linfocitopenia Idiopática CD4-Positiva/complicações , Antivirais/uso terapêutico , Cidofovir , Citosina/análogos & derivados , Citosina/uso terapêutico , Evolução Fatal , Humanos , Leucoencefalopatia Multifocal Progressiva/diagnóstico , Leucoencefalopatia Multifocal Progressiva/tratamento farmacológico , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Compostos Organofosforados/uso terapêutico , T-Linfocitopenia Idiopática CD4-Positiva/diagnóstico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...